Pheon Therapeutics Ltd.

https://www.pheontx.com

LinkedIn: https://www.linkedin.com/company/pheon-therapeutics

Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon’s lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. Pheon is backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT). Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise and track record. *

	Start	2022-08-03 renamed
	Group	Pheon Therapeutics (Group)
	Predecessor	Femtogenix Ltd.
	Industry	antibody-drug conjugate (ADC)
	Industry 2	drug development

	Street	Rothamsted Research West Common Lawes Open Innovation Hub
	City	AL5 2JQ Harpenden, Hertfordshire
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Pheon Therapeutics Ltd.. (9/28/22). "Press Release: Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors". London.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Pheon Therapeutics (Group)

[1] Pheon Therapeutics Ltd.. (9/28/22). "Press Release: Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors". London....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]